Pediatr. praxi. 2025;26(3):183-187 [Dermatol. praxi. 2025;19(2):75-80]

Preschool children successfully treated with dupilumab

MUDr. Michaela Nováková

Dermatovenerologická klinika, FNB a 2. LF UK, Praha

Dermatovenerologická ambulance, IKEM, Praha

Atopic dermatitis (AD) occurs in early childhood in most children, with 80% developing it before the age of 6 years. It is the early childhood experience that significantly affects further psychosocial development. Preschool children learn social skills that involve getting to know peers, communication, listening, and cooperation. Visible manifestations of AD tend to cause stigmatization. They can lead to shyness, low self-esteem, avoidance, and the development of mental disorders. Therefore, adequate and timely treatment is important in children with a severe form of AD, which improves not only the condition of their skin and their mental well-being, but also their quality of life. Treatment options for severe AD in children under 6 years of age are limited because systemic immunosuppressants are not officially approved in this age group and may pose a safety risk. Dupilumab is the first biological therapy approved by the EMA (European Medicines Agency) for children with severe AD from 6 months of age. Treatment with dupilumab with a duration of three years in children aged 6 months to 11 years old with moderate to severe AD has been shown to have an acceptable long-term safety profile and persistent efficacy, which is consistent with the results of studies in other age groups (adolescents and adults). The article presents two case reports of our female paediatric patients of preschool age who have been successfully treated with dupilumab.

Keywords: atopic dermatitis, children, comorbidities, infection, vaccination, dupilumab.

Published: July 4, 2025  Show citation